7.38 0.00 (0.00%)
After hours: 4:12PM EDT
|Bid||7.26 x 1000|
|Ask||7.43 x 3200|
|Day's Range||7.19 - 7.53|
|52 Week Range||5.01 - 38.39|
|Beta (3Y Monthly)||2.13|
|PE Ratio (TTM)||N/A|
|Earnings Date||Aug 7, 2017 - Aug 11, 2017|
|Forward Dividend & Yield||N/A (N/A)|
|1y Target Est||20.50|
La Jolla Pharmaceutical Company (LJPC), a leader in the discovery, development and commercialization of innovative therapies intended to significantly improve outcomes in patients suffering from life-threatening diseases, today announced the appointment of Darryl Wellinghoff as Chief Commercial Officer. “We are excited to welcome Darryl to La Jolla’s leadership team,” said George Tidmarsh, M.D., Ph.D., La Jolla’s President and Chief Executive Officer. “Darryl brings extensive and highly relevant experience and depth of knowledge in sales, marketing, product launch and market access gained as a result of many successful product launches.
SAN DIEGO, March 07, 2019 -- La Jolla Pharmaceutical Company (Nasdaq: LJPC), a leader in the discovery, development and commercialization of innovative therapies intended to.
In 2012 George Tidmarsh was appointed CEO of La Jolla Pharmaceutical Company (NASDAQ:LJPC). This report will, first, examine the CEO compensation levels in comparison to CEO compensation at companies ofRead More...
Investors need to pay close attention to La Jolla Pharmaceutical (LJPC) stock based on the movements in the options market lately.
Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peaks (Biotech stocks hitting 52-week highs on March 4) Abbott Laboratories (NYSE: ABT ) Ascendis Pharma A/S ...
SAN DIEGO, March 04, 2019 -- La Jolla Pharmaceutical Company (Nasdaq: LJPC), a leader in the discovery, development and commercialization of innovative therapies intended to.
SAN DIEGO, Feb. 25, 2019 -- La Jolla Pharmaceutical Company (Nasdaq: LJPC), a leader in the discovery, development and commercialization of innovative therapies intended to.
SAN DIEGO, Feb. 14, 2019 -- La Jolla Pharmaceutical Company (Nasdaq: LJPC) today announced that there will be multiple presentations on GIAPREZA (angiotensin II) at the Society.
NEW YORK, Feb. 05, 2019 -- In new independent research reports released early this morning, Market Source Research released its latest key findings for all current investors,.
Perceptive Advisors slashed its stake in half earlier this month, but La Jolla Chairman Kevin Tang bought enough shares to make him the company’s new top holder.
HENDERSON, NV / ACCESSWIRE / January 10, 2019 / Biotech has started 2019 off with a bang. Below are a few that you should be paying attention to. One that looks poised for a big year, Delcath Systems, ...
La Jolla Pharmaceutical Company (NASDAQ: LJPC ) reported net 2018 sales of $10.1 million for the septic shock treatment Giapreza this week and announced 2019 sales guidance of $24 million to $28 million ...
La Jolla's share price fell to $5.64 by 2:34 pm, down from its close of $10.52 on Friday, after the company said it expects sales of low blood pressure drug Giapreza to hit $24 million-$28 million in 2019, roughly half of what analysts had projected. The pharmaceutical company's stock has been trending downward since late September, when it was trading at more than $22. La Jolla reported a 20% increase during the fourth quarter in sales of Giapreza, first launched in March, with sales of the drug, used to increase blood pressure in patients suffering from septic or distributive shock.
Shares of La Jolla Pharmaceutical Co. plummeted 44% in midday trade Monday to pace all Nasdaq losers, after the company provided downbeat guidance on its key drug that treats dangerously low blood pressure in adults with septic or other disruptive shock. The company said its fourth-quarter sales of Giapreza, which was launched in March 2018, rose 20% from a year ago to $4.2 million, with 2018 sales expected to reach $10.1 million. The Giapreza sales estimates of the two analysts that provided estimates to FactSet ranged from $5.2 million to $6.9 million for the fourth quarter and $11.1 million to $12.8 million for 2018. For 2019, La Jolla Pharmaceuticals said it expects Giapreza sales to rise to $24 million to $28 million, while analyst estimates ranged from $44.3 million to $55.0 million. The stock, on track for the lowest close since September 2013, has now plummeted 68% over the past three months, while the S&P 500 has declined 11%.
- Fourth-Quarter 2018 Net Sales of GIAPREZA Were Approximately $4.2 Million, Up 20% from the Third Quarter of 2018 - - Full-Year 2019 Net Sales Guidance for GIAPREZA of $24.
SAN DIEGO, Jan. 04, 2019 -- La Jolla Pharmaceutical Company (Nasdaq: LJPC), a leader in the discovery, development and commercialization of innovative therapies intended to.
There are several ways to beat the market, and investing in small cap stocks has historically been one of them. We like to improve the odds of beating the market further by examining what famous hedge fund operators such as Carl Icahn and George Soros think. Those hedge fund operators make billions of dollars each […]
CORAL GABLES, FL / ACCESSWIRE / October 25,2018 / Healthcare stocks have helped to boost the US equity markets today. The Select Sector SPDR Healthcare ETF (XLV) has had a strong recovery on Thursday and the broader markets are also surging. The healthcare industry has seen a shakeup recently as new technology innovation and further research on new drugs pushes industry margins.
La Jolla Pharmaceutical (LJPC) delivered earnings and revenue surprises of 3.98% and 2.82%, respectively, for the quarter ended September 2018. Do the numbers hold clues to what lies ahead for the stock?
The San Diego-based company said it had a loss of $1.93 per share. The results beat Wall Street expectations. The average estimate of five analysts surveyed by Zacks Investment Research was for a loss ...